Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to advance Kriya’s portfolio of gene therapies designed to block complement C3 and C5 for retinal diseases using Everads' suprachoroidal delivery device.
Lead Product(s): AAV Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Everads Therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
Kriya acquires a portfolio of Fibroblast Growth Factor 21 (FGF21) assets including Tramontane’s lead program, an adeno-associated virus (AAV) vector designed to express a steady level of the native FGF21 protein, for treating people with NASH.
Lead Product(s): AAV Gene Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Tramontane Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 06, 2023
Details:
The net proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms.
Lead Product(s): Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $430.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 26, 2023
Details:
The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Redpin Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 16, 2022
Details:
Proceeds from this financing will support the advancement of Kriya’s pipeline and continued scaling of its engineering, manufacturing, and computational platforms. Kriya has established an ecosystem for delivering best-in-class technologies and medicines in gene therapy.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 16, 2022
Details:
Twist Biopharma, expects to leverage its antibody discovery and optimization platform to discover novel antibodies against specific targets of interest that will be engineered into Kriya’s proprietary gene therapy technology platform for durable and targeted delivery.
Lead Product(s): Antibody,AAV-based Gene Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Twist Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2022
Details:
Through this agreement, Kriya is advancing gene therapies that are designed to durably express engineered molecules that selectively reduce complement hyperactivity at the site of pathology following one-time administration.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Medical University of South Carolina
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
Details:
Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs. This acquisition serves as the foundation for Kriya’s Rare Disease Division focused on the discovery and development of gene therapies for rare diseases.
Lead Product(s): AAV-mediated Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Warden Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 07, 2022
Details:
Financing proceeds will support the development of Kriya's pipeline, internal discovery engine, and proprietary GMP manufacturing infrastructure. Kriya's initial pipeline includes multiple AAV-based gene therapies for the treatment of metabolic diseases.
Lead Product(s): KT-A112
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: QVT
Deal Size: $80.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 12, 2020